Vera Therapeutics (NASDAQ:VERA) Insider Sells $91,810.26 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) insider William Turner sold 2,187 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $91,810.26. Following the completion of the transaction, the insider owned 45,313 shares in the company, valued at $1,902,239.74. The trade was a 4.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Vera Therapeutics Trading Down 3.7%

Shares of VERA stock opened at $40.79 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. The company has a market cap of $2.86 billion, a price-to-earnings ratio of -8.75 and a beta of 1.16. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $56.05. The firm has a fifty day moving average price of $46.32 and a 200-day moving average price of $35.49.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Wednesday, February 25th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same quarter in the prior year, the firm posted ($0.72) earnings per share. As a group, equities analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Institutional Investors Weigh In On Vera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its holdings in shares of Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after buying an additional 236 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Vera Therapeutics during the fourth quarter valued at $46,000. Aster Capital Management DIFC Ltd bought a new stake in Vera Therapeutics in the 4th quarter valued at $71,000. Quantbot Technologies LP purchased a new stake in Vera Therapeutics in the 2nd quarter worth $51,000. Finally, Sandia Investment Management LP purchased a new stake in Vera Therapeutics in the 4th quarter worth $127,000. Institutional investors own 99.21% of the company’s stock.

Wall Street Analysts Forecast Growth

VERA has been the subject of several analyst reports. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, January 21st. Evercore increased their price objective on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research note on Friday, November 28th. Finally, The Goldman Sachs Group upped their target price on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $78.80.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.